Surgery Today

, Volume 43, Issue 8, pp 865–870 | Cite as

Postoperative outcomes of patients with hepatocellular carcinoma negative for all virus-related markers

  • Ichiro Yamato
  • Tadatoshi Takayama
  • Yutaka Midorikawa
  • Tokio Higaki
  • Hisashi Nakayama
  • Masamichi Moriguchi
  • Yoshiyuki Nakajima
  • Shunichi Matsuoka
  • Masahiro Ogawa
  • Mitsuhiko Moriyama
Original Article



The outcomes of patients with resectable hepatocellular carcinoma (HCC) negative for all virus-related markers have not yet been characterized. This study investigated the outcomes of such patients in comparison to those who had virus-related resectable HCC.


A total of 398 patients with HCC were divided into 2 groups, comprising patients in which all virus-related markers (HBs-Ag, HBs-Ab, HBe-Ag, HBe-Ab, HBc-Ab, HCV-Ab) were negative (all-negative group, n = 63) and those with at least 1 positive virus-related marker (virus-related group, n = 335). The clinical characteristics, surgical data, and survival rates were compared between the groups.


The serum AST (30 vs. 45 IU/l, P < 0.0001) and ALT (21 vs. 42 IU/l, P < 0.0001) levels were significantly lower in the all-negative group than in the virus-related group. The tumor size (4.3 vs. 3.1 cm, P < 0.0001), the prevalence of DM (46.8 vs. 25.4 %, P = 0.001), and BMI (24.8 vs. 22.9, P = 0.0023) were significantly higher in the all-negative group than in the virus-related group. HCC arose from a cirrhotic liver in a significantly higher proportion of patients in the virus-related group than in the all-negative group (20.6 vs. 44.8 %, P = 0.0002). The survival outcomes were not significantly different in the 2 groups (all-negative vs. virus-related: 5-year overall survival rate, 58.2 vs. 55.2 %, P = 0.27), despite such differences in the patients’ characteristics.


The postoperative outcomes of patients with HCC are independent of the presence or absence of hepatitis viral infection.


Hepatocellular carcinoma All negative Virus-related marker Non-B non-C Outcome 


  1. 1.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.PubMedCrossRefGoogle Scholar
  2. 2.
    Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol. 2006;12:7239–49.PubMedGoogle Scholar
  3. 3.
    Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17–26.PubMedCrossRefGoogle Scholar
  4. 4.
    Koorey D. Hepatocellular carcinoma: prevention, detection and treatment… in the real world. Intern Med J. 2007;37:513–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Hainaut P, Boyle P. Curbing the liver cancer epidemic in Africa. Lancet. 2008;371:367–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Pascual S, Irurzun J, Zapater P, Such J, Sempere L, Carnicer F, et al. Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice. Liver Int. 2008;28:682–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol. 2008;43:967–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Kato Y, Nakata K, Omagari K, Furukawa R, Kusumoto Y, Mori I, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer. 1994;74:2234–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Shiratori Y, Shiina S, Zhang PY, Ohno E, Okudaira T, Payawal DA, et al. Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? Cancer. 1997;80:2060–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995;21:650–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Lowell JA, Howard TK, White HM, Shenoy S, Huettner PC, Brennan DC, et al. Serological evidence of past hepatitis B infection in liver donor and hepatitis B infection in liver allograft. Lancet. 1995;345:1084–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Chen Y, Wu W, Li LJ, Lou B, Zhang J, Fan J. Comparison of the results for three automated immunoassay systems in determining serum HBV markers. Clin Chim Acta. 2006;372:129–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Koike K. Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol Res. 2005;33:145–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2005;33:72–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Fan JG, Farrell GC. Prevention of hepatocellular carcinoma in nonviral-related liver diseases. J Gastroenterol Hepatol. 2009;24:712–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349–54.PubMedGoogle Scholar
  18. 18.
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.PubMedCrossRefGoogle Scholar
  19. 19.
    Torisu Y, Ikeda K, Kobayashi M, Hosaka T, Sezaki H, Akuta N, et al. Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: a preliminary report. Hepatol Res. 2007;37:517–23.PubMedCrossRefGoogle Scholar
  20. 20.
    Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–21.Google Scholar
  21. 21.
    Junior WS, Nonino-Borges CB. Clinical predictors of different grades of nonalcoholic fatty liver disease. Obes Surg 2012;22:248–52.PubMedCrossRefGoogle Scholar
  22. 22.
    Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, et al. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol Res. 2010;40:870–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710–23.PubMedCrossRefGoogle Scholar
  24. 24.
    Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. 2008;47:1856–62.PubMedCrossRefGoogle Scholar
  26. 26.
    Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130:1639–48.PubMedCrossRefGoogle Scholar
  27. 27.
    Japan Liver Cancer Study Group. Classification of primary liver cancer, 2nd English edition. Tokyo: Kanehara Press Co.; 2003.Google Scholar

Copyright information

© Springer 2012

Authors and Affiliations

  • Ichiro Yamato
    • 1
    • 2
  • Tadatoshi Takayama
    • 1
  • Yutaka Midorikawa
    • 1
  • Tokio Higaki
    • 1
  • Hisashi Nakayama
    • 1
  • Masamichi Moriguchi
    • 1
  • Yoshiyuki Nakajima
    • 2
  • Shunichi Matsuoka
    • 3
  • Masahiro Ogawa
    • 3
  • Mitsuhiko Moriyama
    • 3
  1. 1.Department of Digestive SurgeryNihon University School of MedicineTokyoJapan
  2. 2.Department of SurgeryNara Medical UniversityNaraJapan
  3. 3.Division of Gastroenterology and Hepatology, Department of MedicineNihon University School of MedicineTokyoJapan

Personalised recommendations